Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,420 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Active capsule Clear all

Conditions: ME/CFS, IBS - Irritable Bowel Syndrome
Interventions: Floradapt Intensive GI, Placebo; Drug · Other
Lead sponsor: Nova Southeastern University; Other
Eligibility: 45 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Enteric Hyperoxaluria
Interventions: Reloxaliase, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 57 more

Conditions: Human Abuse Potential
Interventions: Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy, Menopause
Interventions: Dietary Supplement with Proprietary Herbal Extract Blend and GABA, Placebo; Dietary Supplement · Other
Lead sponsor: Olly, PBC; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: Zasocitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Glen Burnie, Maryland • Tyler, Texas

Conditions: Fatty Liver
Interventions: Polyunsaturated fatty acid (Opti-EPA), Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Community Acquired Pneumonia
Interventions: Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg; Drug
Lead sponsor: IASO Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 13
States / cities: Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Taletrectinib, Placebo; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 50
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more

Conditions: Opioid-Related Disorders
Interventions: Deep Brain Stimulation; Device
Lead sponsor: West Virginia University; Other
Eligibility: 22 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions: Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 2,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 221
States / cities: Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Delavirdine mesylate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 45
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more

Conditions: Peanut Allergy
Interventions: AR101; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 47
States / cities: Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more

Conditions: Burns, Second Degree Burn, Wounds and Injuries
Interventions: Drug: 4-Aminopyridine, Placebo; Drug · Other
Lead sponsor: John Elfar; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Interventions: FT-4101, FT-4101 placebo, Deuterated Water; Drug · Other
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Chula Vista, California • Montclair, California

Conditions: COPD
Interventions: Curcumin therapy, Placebo, Standard care; Dietary Supplement · Other
Lead sponsor: Danbury Hospital; Other
Eligibility: 40 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Danbury, Connecticut

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Sunphenon, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Westwood, Kansas

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 36
States / cities: Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more

Conditions: Subacromial Pain Syndrome
Interventions: dry needling, spinal manipulation, mobilization, exercise, modalities; Other
Lead sponsor: Alabama Physical Therapy & Acupuncture; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cockeysville, Maryland

Conditions: Primary Membranous Nephropathy
Interventions: Zanubrutinib, Tacrolimus; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 1 more

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 106
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more

Conditions: Temporomandibular Disorders
Interventions: Propranolol ER, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Gainesville, Florida • Buffalo, New York • Chapel Hill, North Carolina

Search by objective public record fields.

The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

Assessment of Abuse Potential of Cebranopadol in Humans

One Week Clinical Study in Subjects With Menopausal Symptoms

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

PALISADE Follow-on Study (ARC004)

4-Aminopyridine to Treat Skin Burns

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

Curcumin in Management of Chronic Obstructive Pulmonary Disease

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

Dry Needling and Manipulation vs. Mobilization, Exercise and Interferential Electrotherapy for Shoulder Impingement (Subacromial Pain Syndrome)

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Study of Orofacial Pain and PropRANOlol